• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

    1.080 -0.150 (-12.20%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about SciSparc Ltd. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    News headline image
    S&P 500 Edges Lower, SciSparc Shares Surge ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    Dow Gains 50 Points, SEALSQ Shares Plummet ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall ↗
     
    Via Benzinga
    News headline image
    SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment ↗
    SciSparc Ltd. shares are soaring after its merger-bound AutoMax Motors received its first shipment of JAC vehicles. The shipment positions AutoMax to begin marketing and sales activities for JAC Motors... 
    Via Benzinga
    News headline image
    Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome ↗
    SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon. 
    Via Benzinga
    News headline image
    SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Files International Patent For Ibogaine Combination Therapy ↗
    Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy. 
    Via Benzinga
    Topics Intellectual Property
    News headline image
    Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients ↗
    SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at... 
    Via Benzinga
    News headline image
    SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy ↗
    SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milestones of $3M in cash plus royalties. 
    Via Benzinga
    News headline image
    Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Nasdaq Jumps Over 2%; Walmart Earnings Top Views ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.